Altimmune is a clinical stage immunotherapeutics company focused on the discovery and development of products to stimulate immune responses for the prevention and treatment of diseases. The company's product candidates include: HepTcell, an immunotherapeutic for patients infected with the hepatitis B virus; ALT-702, a tumor immunostimulant designed to elicit or improve immune responses to cancers; NasoVAX, an intranasally administered recombinant influenza vaccine which stimulates an immune response; NasoShield, an anthrax vaccine designed to provide protection after a single intranasal administration; and SparVax-L, a recombinant protein-based anthrax vaccine designed to require fewer doses.

Mid Penn Bancorp is a bank holding company. Through its subsidiary Mid Penn Bank (the Bank), the company is engaged in accepting deposits and loans. The Bank engages in commercial banking and trust business, making available to the community a range of financial services, including, but not limited to, mortgage and home equity loans, secured and unsecured commercial and consumer loans, lines of credit, construction financing, farm loans, community development and local government loans and various types of time and demand deposits. The Bank also provides other services such as online banking, telephone banking, cash management services, automated teller services and safe deposit boxes.